Histone deacetylase inhibitors upregulate Snail via Smad2/3 phosphorylation and stabilization of Snail to promote metastasis of hepatoma cells

Hepatocellular carcinoma (HCC) remains the third most common cause of cancer-related mortality. Resection and transplantation are the only curative treatments available, but are greatly hampered by high recurrence rates. Histone deacetylase inhibitors (HDACIs) are considered to be promising anticancer agents in drug development. Currently, four HDACIs have been granted Food and Drug Administration (FDA) approval for cancer. HDACIs have shown significant efficacy in hematological malignancies. However, they have limited effects in epithelial cell-derived cancers, including HCC, and the mechanisms of these are not elucidated.

Source: Cancer Letters - February 3, 2018 Category: Cancer & Oncology Authors: Wei Xu, Hao Liu, Zhi-Gang Liu, Hong-Sheng Wang, Fan Zhang, Hao Wang, Ji Zhang, Jing-Jing Chen, Hong-Jun Huang, Yuan Tan, Meng-Ting Cao, Jun Du, Qiu-Gui Zhang, Guan-Min Jiang Tags: Original Articles Source Type: research